LMN-201 for Prevention of C. Difficile Infection Recurrence

Phase 2

Recruiting

• Conditions: Clostridioides Difficile Infection
• Interventions: Drug: Placebo; Drug: LMN-201

• Registration Number: NCT05330182
• Lead Sponsor: Lumen Bioscience, Inc.

Brief Summary

This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-04-08
• Study First Submitted QC: 2022-04-08
• Study First Posted: 2022-04-15
• Study Start: 2024-08-29
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-10
• Last Update Posted: 2025-03-11
• Primary Completion: 2025-12-01
• Study Completion: 2026-04-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 375

Inclusion Criteria

1. Male or female, aged 18 or older.
2. Diagnosis of CDI defined as a new or recent history of 3 or more bowel movements per day with a loose or watery consistency (Bristol Stool Scale 5, 6, or 7); a positive stool C. difficile toxin B immunoassay (stool collected no more than 7 days before first dose of LMN-201/placebo), and no other likely explanation for diarrhea. NOTE: Diarrhea is not required to be present on the day of enrollment.
3. Provision of signed and dated informed consent form.
4. Scheduled to receive or planning to receive a ≤28-day course of SOC antibiotic therapy for CDI. Participant must have been diagnosed with CDI for 7 or fewer days at time of initial study drug administration. SOC antibiotic therapy is defined as the receipt of oral fidaxomicin or oral metronidazole or oral vancomycin (see Section 8.2.6)
5. May be on systemic antibiotics for an infection unrelated to the gastrointestinal tract.
6. Ability to take oral medication and willingness to adhere to the study medication regimen.
7. Stated willingness and ability to comply with all study procedures and availability for the duration of the study and investigator believes individual will complete the study.
8. Access to a mobile smartphone.
9. For females of reproductive potential: use of highly effective contraception for at least 4 weeks prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of study drug administration.
10. For males of reproductive potential: agreement to use condoms or other methods to ensure effective contraception with partner during study participation and for an additional 4 weeks after the end of study drug administration.

Exclusion Criteria

1. Fulminant C. difficile colitis.

2. Admitted or expect to be admitted to an intensive care unit.

3. Underlying gastrointestinal disorder characterized by diarrhea including but not limited to chronic ulcerative colitis, Crohn's disease, celiac sprue, short bowel syndrome, dumping syndrome following gastrectomy, pancreatic insufficiency, enteric parasitic infection, viral enteritis, bacterial enteritis (salmonella, shigella, ETEC, etc.).

4. Neutropenia (absolute neutrophil count of < 1000 per microliter for any reason).

5. Current or previous treatment in past 3 months with any therapy likely to influence the outcome of this study, including but not limited to the following:

   1. Bezlotoxumab (Zinplava, Merck & Co.), or another antibody against C. difficile toxin(s)
   2. C. difficile vaccine
   3. SER-109 (Seres Therapeutics)
   4. CP101 (Finch Therapeutics)
   5. VE303 (Vedanta Therapeutics)
   6. Fecal microbiota transplant
   7. Current therapy with oral exchange resins
   8. Protracted exposure to mu-agonist opioids and/or anticholinergic medication prescribed for diarrheal symptoms (unable to stop mu-agonist opioid treatment unless on a stable dose as of onset of diarrhea and no increase in dose planned for the duration of the study.)

6. Treatment with SOC antibiotic therapy is planned for longer than a 28-day period.

7. Pregnancy, anticipated pregnancy, or breastfeeding.

8. Inability or unwillingness to swallow numerous, relatively large capsules containing study drug or placebo because of a swallowing disorder or dysphagia.

9. Inability to pass swallowed capsules into the distal small intestine because of gastroparesis, repetitive vomiting, or anatomic narrowing in the esophagus, stomach, or small intestine.

10. Psychiatric illness that would affect compliance with medications, study capsules, or follow-up.

11. Status as an inmate, residential mental health program, or residential substance abuse program.

12. Terminal illness with limited life expectancy of less than 24 weeks.

13. Poor concurrent medical risks with clinically significant co-morbid disease such that, in the opinion of the investigator, the patient should not be enrolled.

14. Any other condition that, in the opinion of the investigator, would jeopardize the safety or rights of the individual, would make it unlikely for the individual to complete the study, or would confound the results of the study.

    • Note: Use of probiotics and other food supplements (e.g., yogurt, kefir, kimchi, etc.) are not exclusionary.
    • Note: Assuming participants meet all of the inclusion criteria and none of the exclusion criteria, participants with underlying malignancy with a good life expectancy in the study are not excluded.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	-
LMN-201	LMN-201	-
Sentinel Cohort	LMN-201	-

Primary Outcome Measures

Name	Time	Method
Proportion of participants who achieve global cure	Up to 16 weeks after initiation of therapy	Proportion of total participants with both successful initial CDI treatment and no CDI recurrence during the Prevention and Observation Phases (by treatment assignment).

Trial Locations

Locations (17)

Kaiser Permanente; 🇺🇸 Los Angeles, California, United States

Bridgeport Hospital; 🇺🇸 Bridgeport, Connecticut, United States

Gastroenterology Center of Connecticut; 🇺🇸 Hamden, Connecticut, United States

GI PROS Research; 🇺🇸 Naples, Florida, United States

Metro Infectious Disease Consultants - Atlanta; 🇺🇸 Decatur, Georgia, United States

Snake River Research; 🇺🇸 Idaho Falls, Idaho, United States

Metro Infectious Disease Consultants, LLC; 🇺🇸 Burr Ridge, Illinois, United States

DM Clinical Research; 🇺🇸 Oak Lawn, Illinois, United States

Baptist Health Research; 🇺🇸 Lexington, Kentucky, United States

University of Minnesota; 🇺🇸 Minneapolis, Minnesota, United States

Mercury Street Medical; 🇺🇸 Butte, Montana, United States

Quality Clinical Research, Inc; 🇺🇸 Omaha, Nebraska, United States

Weill Cornell Medicine; 🇺🇸 New York, New York, United States

IMA Clinical Research; 🇺🇸 Mount Airy, North Carolina, United States

The Clinical Trials Network, LLC; 🇺🇸 Willoughby, Ohio, United States

MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States

Clinical Alliance for Infectious Diseases - Infectious Diseases, LLC; 🇺🇸 Annandale, Virginia, United States